Francesca P.
- Country
- Italy
- Department
- UOC Hematology
Research Overview
- Evaluation of INCA033989 Efficacy and Safety in Patients with Myelofibrosis or Essential Thrombocythemia within Myeloproliferative Neoplasms
- Phase 1 Evaluation of JNJ-88549968, a T-cell Redirecting Antibody, in Patients with CALR-mutated Myeloproliferative Neoplasms
- A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
Data & Insights
Has run more than one trial at 209 of 348 partner sites.
Specializations
Myelofibrosis Research
This investigator specializes in studying various therapeutic approaches for myelofibrosis, including both primary and secondary forms. Their research encompasses treatments for patients with JAK inhibitor-naïve myelofibrosis and those who have become unresponsive to JAK inhibitors.
- Novel therapeutic combinations
- Treatment resistance management
- Spleen volume reduction approaches
Myeloproliferative Disorders
The investigator focuses on treating various myeloproliferative neoplasms, including essential thrombocythemia and polycythemia vera. Their work includes evaluation of novel agents for managing these conditions.
- Cytoreductive therapies
- Disease response assessment
- Treatment of high-risk patients
Hematologic Complications
Research activities include addressing anemia associated with myeloproliferative disorders and managing thrombocytopenia. The investigator studies treatments for complex hematologic manifestations.
- Transfusion dependency management
- Blood count control strategies
- Symptom burden reduction
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.